TALTZ

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, Spain, UK.

Active ingredients

The drug TALTZ contains one active pharmaceutical ingredient (API):

1	Ixekizumab UNII BTY153760O - IXEKIZUMAB
	Ixekizumab is an IgG4 monoclonal antibody that binds with high affinity (<3 pM) and specificity to interleukin 17A (both IL-17A and IL-17A/F). Elevated concentrations of IL-17A have been implicated in the pathogenesis of psoriasis by promoting keratinocyte proliferation and activation, as well as in the pathogenesis of psoriatic arthritis. Neutralisation of IL-17A by ixekizumab inhibits these actions.
	Read more about Ixekizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TALTZ Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AC13		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11032P, 11033Q, 11623R, 12209N, 12217B
BR	Câmara de Regulação do Mercado de Medicamentos	507618030020801, 507618030020901, 507618030021001, 507618030021101, 507618030021201, 507618030021301
CA	Health Products and Food Branch	02455102, 02455110
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	158-MBE-0620
EE	Ravimiamet	1717073, 1717084, 1717095, 1717107, 1717118, 1717129
ES	Centro de información online de medicamentos de la AEMPS	1151085001, 1151085004
FI	Lääkealan turvallisuus- ja kehittämiskeskus	168388, 589343
FR	Base de données publique des médicaments	60241034, 61077659
GB	Medicines & Healthcare Products Regulatory Agency	328137, 336899
HK	Department of Health Drug Office	65209, 65211
IE	Health Products Regulatory Authority	88600, 88737
IL	מִשְׂרַד הַבְּרִיאוּת	7985
IT	Agenzia del Farmaco	044863013, 044863025, 044863037, 044863049, 044863052, 044863064
JP	医薬品医療機器総合機構	3999442G1023, 3999442G2020
LT	Valstybinė vaistų kontrolės tarnyba	1080174, 1080175, 1080176, 1080177, 1080178, 1080179
NL	Z-Index G-Standaard, PRK	132039, 132047
PL	Rejestru Produktów Leczniczych	100370679
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67999001, W67999002, W67999003, W68000001, W68000002, W68000003
SG	Health Sciences Authority	15501P
US	FDA, National Drug Code	0002-1445, 0002-7724